Quantifying the costs, outcomes, and value of care for acute myocardial infarction (AMI) to inform efficient, high-value resource allocation for AMI management in Singapore

Coronary artery disease is a leading cause of death globally and in Singapore, accounting for over one third of deaths. Advances in acute myocardial infarction (AMI) care have improved survival and long-term outcomes. Consequently, the number of people living with a history of AMI has increased.

However, AMI survivors experience higher morbidity and require more healthcare services. They also incur greater healthcare expenditures over time. In Singapore, the economic burden of cardiovascular disease is estimated at USD 8.1 billion (SGD 11.5 billion). International evidence suggests costs are highest in the first year after AMI, varying by setting and patient mix. These overseas estimates may not reflect Singapore’s local care pathways, prices, or utilisation patterns. Existing studies often follow patients for six years or less, limiting understanding of longer-term outcomes and costs.

This study will use Singapore real-world data to examine healthcare use, medical costs, and survival after AMI over a longer period. It will also compare people with AMI to a similar group of people without AMI but with similar age, sex, and health conditions. This will help show the extra burden linked to AMI more clearly. The findings will provide local evidence to support better healthcare planning and more efficient use of resources in Singapore.